ORIGINAL ARTICLES

BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reports

J R Toro¹, M-H Wei^1,2, G M Glenn¹, M Weinreich¹, O Toure¹, C Vocke³, M Turner⁴, P Choyke⁵, M J Merino⁶, P A Pinto³, S M Steinberg⁷, L S Schmidt^2,3, W M Linehan³

¹ Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA
² Basic Research Program, SAIC–Frederick Inc, Frederick, Maryland, USA
³ Urologic Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
⁴ Dermatology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
⁵ Molecular Imaging Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
⁶ Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA
⁷ Biostatistics and Data Management Section, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA

Dr J R Toro, Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Executive Plaza South, Room 7012, Rockville, MD 20892-7231, USA; torojo{at}mail.nih.gov

Background: Birt–Hogg–Dubé syndrome (BHDS) (MIM 135150 [OMIM] ) is an autosomal dominant predisposition to the development of follicular hamartomas (fibrofolliculomas), lung cysts, spontaneous pneumothorax, and kidney neoplasms. Germline mutations in BHD are associated with the susceptibility for BHDS. We previously described 51 BHDS families with BHD germline mutations.

Objective: To characterise the BHD mutation spectrum, novel mutations and new clinical features of one previously reported and 50 new families with BHDS.

Methods: Direct bidirectional DNA sequencing was used to screen for mutations in the BHD gene, and insertion and deletion mutations were confirmed by subcloning. We analysed evolutionary conservation of folliculin by comparing human against the orthologous sequences.

Results: The BHD mutation detection rate was 88% (51/58). Of the 23 different germline mutations identified, 13 were novel consisting of: four splice site, three deletions, two insertions, two nonsense, one deletion/insertion, and one missense mutation. We report the first germline missense mutation in BHD c.1978A>G (K508R) in a patient who presented with bilateral multifocal renal oncocytomas. This mutation occurs in a highly conserved amino acid in folliculin. 10% (5/51) of the families had individuals without histologically confirmed fibrofolliculomas. Of 44 families ascertained on the basis of skin lesions, 18 (41%) had kidney tumours. Patients with a germline BHD mutation and family history of kidney cancer had a statistically significantly increased probability of developing renal tumours compared to patients without a positive family history (p = 0.0032). Similarly, patients with a BHD germline mutation and family history of spontaneous pneumothorax had a significantly increased greater probability of having spontaneous pneumothorax than BHDS patients without a family history of spontaneous pneumothorax (p = 0.011). A comprehensive review of published reports of cases with BHD germline mutation is discussed.

Conclusion: BHDS is characterised by a spectrum of mutations, and clinical heterogeneity both among and within families.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Warwick, G., Izatt, L., Sawicka, E. (2008). Familial spontaneous pneumothorax: importance of screening for renal tumours. Eur Respir J 32: 1672-1673 [Full Text]